Immuneel Therapeutics Raises Over Rs. 100 Crore, A Big Push For India’s CAR-T Cancer Therapy Market

Immuneel Therapeutics has raised over Rs. 100 crore in a Series B funding round, giving India’s advanced cancer treatment space another important moment. The Bengaluru-based biotech startup is working in cell and gene therapy, a field that is still young in India but could become highly important for patients with difficult-to-treat cancers.

The round was led by new investors including Singularity AMC and Rainmatter by Zerodha, along with participation from several high-net-worth individuals. Existing backers such as Kiran Mazumdar-Shaw, Eight Roads Ventures and F-Prime Capital also joined the round.

Immuneel is trying to build a serious healthcare platform from India for CAR-T therapy, a complex treatment that uses a patient’s own immune cells to fight cancer. For a country where advanced cancer care is often expensive and limited to a few hospitals, this funding could help expand access, manufacturing and research.

What Immuneel Therapeutics Does

Immuneel Therapeutics works on cell and gene therapies, with a major focus on CAR-T therapy. In simple words, CAR-T therapy takes certain immune cells from a patient, modifies them in a lab, and sends them back into the body to identify and attack cancer cells. This is very different from regular chemotherapy. Chemotherapy attacks fast-growing cells, which can include cancer cells as well as healthy cells. CAR-T therapy is more targeted, though it is also complex, expensive and needs strong medical infrastructure.

Immuneel’s main focus is blood cancers such as lymphoma and leukemia. Its product Qartemi is being commercialized for Non-Hodgkin Lymphoma, and the company is also working on a wider pipeline of next-generation cell and gene therapies.

Founders And Company Background

Immuneel Therapeutics was founded in 2018-2019, with public profiles mentioning both years across different sources. Its key co-founders are Kiran Mazumdar-Shaw, founder and executive chairperson of Biocon; Dr. Siddhartha Mukherjee, oncologist, author and cancer researcher; and Dr. Kush M Parmar, physician-investor and managing partner at 5AM Ventures.

That founding team gives the company a mix of biotech business experience, clinical research depth and global life sciences investing knowledge. This matters because cell therapy is not a simple consumer-tech business. It needs scientific credibility, hospital partnerships, regulatory discipline, manufacturing quality and patient trust.

The company is currently led by CEO Amit Mookim, who has said the latest funding will help Immuneel move into its next phase after Qartemi’s commercial launch.

How The New Funding Will Be Used

Immuneel plans to use the fresh capital for four broad goals.

1. First, it wants to expand its Good Manufacturing Practice manufacturing capacity. GMP is a quality system used in pharma and biotech manufacturing to make sure therapies are produced safely and consistently.
2. Second, the company will support the commercial rollout of Qartemi. This is important because launching a therapy is only one part of the journey. Patients, hospitals, doctors and payers also need access, awareness and affordability support.
3. Third, Immuneel will invest in research and development for newer cell and gene therapy programs. This could help it move beyond one product and build a stronger biotech pipeline.
4. Fourth, the company is looking at international expansion across Asia-Pacific and the Middle East. If executed well, this could position Immuneel as an India-built advanced therapy company with global ambitions.

Why This Funding Matters For India

India has strong doctors, hospitals and scientific talent, but advanced therapies like CAR-T have historically been costly and difficult to access. Imported CAR-T treatments in global markets can be extremely expensive, often putting them beyond the reach of many Indian families.

Immuneel’s larger promise is affordability with quality. If India can manufacture and deliver such therapies locally, treatment costs may become more manageable compared with Western markets. That does not mean CAR-T will suddenly become cheap, but local production can make a meaningful difference.

A practical example makes this easier to understand. If a patient needs a highly specialized therapy that must be imported or processed abroad, costs and timelines rise sharply. But if the therapy can be manufactured through a compliant facility in India and delivered through local hospital networks, the care pathway can become faster and potentially more affordable.

The Bigger Market Opportunity

Cancer treatment is moving toward personalization. Instead of treating every patient in the same way, doctors increasingly look at cancer type, genetic markers, immune response and treatment history. CAR-T fits into this shift because it uses the patient’s own cells as part of the treatment.

For investors, this makes Immuneel part of a larger health-tech and biotech trend. India has already seen growth in digital health, diagnostics, medical devices and pharma manufacturing. Cell and gene therapy could become the next serious frontier, though it will require patience and heavy capital.

Unlike mobile apps or quick-commerce startups, biotech companies usually take longer to scale. Clinical trials, approvals, hospital adoption and safety monitoring all take time. That makes funding rounds like this important because the company needs long-term capital before the business can mature fully.

Competitors And Market Landscape

Immuneel operates in a specialized space, so its competition is not like a normal startup market with dozens of similar apps. Its competitors and comparable players include Indian and global companies working on CAR-T, oncology, cell therapy and advanced cancer treatments.

In India, ImmunoACT is an important name because it developed NexCAR19, India’s first indigenous CAR-T cell therapy. Globally, companies such as Novartis, Gilead’s Kite Pharma, Bristol Myers Squibb and Legend Biotech are known for CAR-T and cell therapy products.

Immuneel’s edge will depend on affordability, manufacturing quality, clinical results, doctor adoption, hospital partnerships and how quickly it can expand beyond one therapy. In advanced healthcare, trust is built slowly. Strong science matters more than hype.

What Patients And Families Should Understand

CAR-T therapy sounds exciting, but it is not a general cancer cure for everyone. It is used for specific cancer types and usually after doctors assess whether the patient is eligible. It can also have side effects and requires close hospital supervision.

So, while Immuneel’s funding is good news for India’s biotech ecosystem, patients should always speak to qualified oncologists before considering any treatment. Startup funding does not replace medical advice, and treatment decisions should be based on diagnosis, stage, prior therapy, clinical suitability and doctor guidance.

Conclusion With Key Takeaways

Immuneel Therapeutics’ over Rs. 100 crore Series B round is a major development for India’s advanced cancer therapy space. The funding strengthens the company’s plan to scale CAR-T manufacturing, expand Qartemi’s commercial rollout, build its research pipeline and explore global markets.

Key takeaways

• Immuneel Therapeutics has raised over Rs. 100 crore in Series B funding.
• The round included Singularity AMC, Rainmatter by Zerodha, HNIs and existing investors such as Kiran Mazumdar-Shaw, Eight Roads Ventures and F-Prime Capital.
• The company is focused on CAR-T cell therapy, mainly for blood cancers such as lymphoma and leukemia.
• Immuneel was co-founded by Kiran Mazumdar-Shaw, Dr. Siddhartha Mukherjee and Dr. Kush M Parmar.

The funding could help India build more affordable, locally manufactured advanced cancer treatment options.

Facts Input- MC